Anti-PD-1 MAb Market size was valued at USD XX Billion in 2024 and is projected to reach USD YY Billion by 2033, exhibiting a CAGR of ZZ% from 2026 to 2033.
The Anti-PD-1 Monoclonal Antibody (mAb) market in South Korea is experiencing significant growth, driven by the rising prevalence of cancer and advancements in immunotherapy. In 2023, the South Korean cancer immunotherapy market, which includes Anti-PD-1 mAbs, generated a revenue of USD 2,294.1 million and is projected to reach USD 4,715.7 million by 2030, reflecting a compound annual growth rate (CAGR) of 10.8% from 2024 to 2030. Monoclonal antibodies represented the largest segment, accounting for 68.05% of the market share in 2023.
Leading pharmaceutical companies such as Bristol-Myers Squibb and Merck & Co. have established a strong presence in South Korea with their Anti-PD-1 therapies, Opdivo and Keytruda, respectively. Opdivo has been approved for multiple indications, including melanoma, non-small cell lung cancer, and renal cell carcinoma. The approval of these therapies has set a benchmark in oncology, demonstrating the effectiveness of immune checkpoint inhibitors.
Local industry players are also making notable contributions. Samsung Biologics, a prominent South Korean biotechnology company, has expanded its manufacturing capabilities to support the growing demand for biologics, including monoclonal antibodies. The company has built four manufacturing plants with a combined capacity exceeding 600,000 liters and began construction of a fifth plant in Incheon in 2023. Upon completion, these facilities will collectively offer up to 784,000 liters of biomanufacturing capacity, positioning Samsung Biologics as a key player in the global biopharmaceutical manufacturing sector.
Despite the robust growth trajectory, the market faces challenges such as the high cost of Anti-PD-1 therapies, which can limit patient access. The average cost of these inhibitors ranges from $10,000 to $15,000 per month, leading to substantial financial burdens on patients and healthcare systems. Additionally, adverse side effects associated with immune checkpoint inhibitors can deter some patients from pursuing these treatments.
In response to these challenges, the South Korean healthcare industry is focusing on developing biosimilars to make treatments more affordable and accessible. The introduction of biosimilars is expected to enhance patient access to Anti-PD-1 therapies and stimulate market growth. Furthermore, ongoing research into combination therapies aims to improve treatment efficacy and patient outcomes, addressing some of the limitations of current monotherapies.
The South Korean Anti-PD-1 mAb market is poised for continued expansion, driven by technological advancements, strategic collaborations, and a commitment to addressing the healthcare needs of the population. As the market evolves, stakeholders are expected to focus on enhancing affordability and accessibility to ensure that more patients can benefit from these life-saving therapies.
Get an In-Depth Research Analysis of the South Korea Anti-PD-1 MAb Market Size And Forecast [2025-2032]
Bristol Myers Squibb
Merck
Junshi Pharma
Innovent Biologics Inc
Hengrui Medicine
Beijing Beigene
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea Anti-PD-1 MAb Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea Anti-PD-1 MAb Market
Nivolumab
Pembrolizumab
Other Anti-PD-1 Antibodies
Non-Small Cell Lung Cancer (NSCLC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Renal Cell Carcinoma (RCC)
Other Oncology Indications
Intravenous (IV)
Subcutaneous (SC)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Adult Patients
Pediatric Patients
Geriatric Patients
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea Anti-PD-1 MAb Market Research Analysis
1. Introduction of the South Korea Anti-PD-1 MAb Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea Anti-PD-1 MAb Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea Anti-PD-1 MAb Market, By Type
6. South Korea Anti-PD-1 MAb Market, By Application
7. South Korea Anti-PD-1 MAb Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea Anti-PD-1 MAb Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/